ApoE Genotyping Analysis in Patients With Suspected Non-haemorrhagic Amyloid Angiopathy

Ischaemic microangiopathic features have recently been incorporated into the criteria for cerebral amyloid angiopathy (CAA).

ApoE genotyping (presence of the E4 allele) is routinely used to help determine the aetiology of a haemorrhagic microangiopathy found on MRI.

Chronic ischaemic disease in CAA is characterised by the presence of :

* multispot pattern on the FLAIR sequence * severe periventricular FLAIR hypersignals with posterior predominance

The main aim of this study was therefore to analyse the frequency of the presence of one (or two) E4 allele(s) on ApoE genotyping in patients with suspected CAA based on ischaemic MRI involvement with a typical radiological pattern.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Amyloid Angiopathy Amyloidosis Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebral Amyloid Angiopathy Cerebral Arterial Diseases Cerebrovascular Disorders Intracranial Arterial Diseases Metabolic Diseases Nervous System Diseases Nutritional and Metabolic Diseases Proteostasis Deficiencies Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de Nîmes

Nîmes, Gard, 30029, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with ischaemic stroke (from causes other than CAA, as CAA is not a frequent cause of ischaemic stroke) with associated stigmata of microangiopathy on MRI that may suggest associated CAA.
Patients treated at Nîmes University Hospital

Exclusion criteria

Patient refusing to participate

Treatment and study plan

Primary outcomes

ApoE genotypage

Time frame: baseline

To analyse the frequency of the presence of one (or two) E4 allele(s) on ApoE genotyping in patients with suspected AAC. Endpoint: presence of the E4 allele (Yes/No).

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nīmes

Other

Registry information

Acronym: CAA-WMH-ApoE

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2025
First posted: Feb 5, 2025
Registry last updated: Jun 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed